Michael R. Megna Sells 15,211 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 15,211 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $28.75, for a total transaction of $437,316.25. Following the sale, the chief accounting officer now directly owns 32,546 shares of the company’s stock, valued at approximately $935,697.50. The trade was a 31.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Kiniksa Pharmaceuticals Trading Up 2.4%

Shares of Kiniksa Pharmaceuticals stock opened at $30.23 on Friday. The firm’s 50 day simple moving average is $24.27 and its two-hundred day simple moving average is $21.90. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -215.91 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $30.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.25) earnings per share. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KNSA. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.80.

Institutional Trading of Kiniksa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Kiniksa Pharmaceuticals by 6.4% in the first quarter. Rhumbline Advisers now owns 62,700 shares of the company’s stock worth $1,393,000 after purchasing an additional 3,745 shares during the last quarter. Strs Ohio purchased a new position in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $595,000. Acadian Asset Management LLC raised its position in Kiniksa Pharmaceuticals by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock worth $22,961,000 after buying an additional 651,700 shares during the last quarter. Fred Alger Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the 1st quarter valued at approximately $485,000. Finally, Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.